Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals-Reference-Cited by-同舟云学术

Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals

Published:2018-03-23 Issue:6 Volume:67 Page:965-980
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Arranz-Nicolás Javier,Ogando Jesús,Soutar Denise,Arcos-Pérez Raquel,Meraviglia-Crivelli Daniel,Mañes Santos,Mérida Isabel^ORCID,Ávila-Flores Antonia^ORCID

Funder

Ministerio de Economía, Industria y Competitividad (MINECO); Spanish Ministry of Health (Instituto de Salud Carlos III); Madrid regional government (IMMUNOTHERCAM Consortium).

Ministerio de Economía, Industria y Competitividad (MINECO); Madrid regional government (IMMUNOTHERCAM Consortium).

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2154-8/fulltext.html

Reference50 articles.

1. Singh N, Frey NV, Grupp SA, Maude SL (2016) CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol 17(6):28. https://doi.org/10.1007/s11864-016-0406-4

2. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239

3. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948):1109–1117. https://doi.org/10.1016/S0140-6736(14)60958-2

4. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. https://doi.org/10.1016/S1470-2045(15)70076-8

5. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20(16):4262–4273. https://doi.org/10.1158/1078-0432.CCR-13-2627

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diacylglycerol kinases: A look into the future of immunotherapy;Advances in Biological Regulation;2023-11

2. Wiskott-Aldrich syndrome protein interacts and inhibits diacylglycerol kinase alpha promoting IL-2 induction;Frontiers in Immunology;2023-04-17

3. Lymphocytic Choriomeningitis Virus Clone 13 Infection Results in CD8 T Cell–Mediated Host Mortality in Diacylglycerol Kinase α–Deficient Mice;The Journal of Immunology;2023-03-05

4. Modulating T Cell Responses by Targeting CD3;Cancers;2023-02-13

5. The expanding role for small molecules in immuno-oncology;Nature Reviews Drug Discovery;2022-08-18